Orencia Articles

Bristol-Myers and Simcere agree to co-develop/commercialize Orencia SC in China

14 June 2013

Bristol-Myers Orencia equals Humira in head-to-head AMPLE RA study

12 June 2013

UK's NICE gives final guidance on Esbriet, Orencia and Xolair

24 April 2013

NICE green light for earlier use of Bristol-Myers' Orencia

8 March 2013

UK's NICE draft guidance recommends Bristol-Myers Orencia for RA

6 December 2012

Bristol-Myers' subcutaneous Orencia OKed in EU; Biologics for RA

7 October 2012

More news at EULAR from Novartis, J&S and B-MS

7 June 2012

US rheumatologists continue to increase use of biologics for RA treatment

29 March 2012

Bristol-Myers gets more rights to Ono antibody in exchange for Japan co-rights to Orencia

22 September 2011

UK’s NICE recommends Merck & Co’s Simponi but not B-MS’s Orencia

26 August 2011

US FDA backs SC form of B-MS Orencia; extends review of Pfizer’s Prevnar 13

1 August 2011

Draft guidance from UK’s NICE rejects Bristol-Myers Orencia

31 March 2011

Good news for Britain’s RA patients as NICE backs NHS use of MabThera and Humira, as well as Enbrel, Remicade, Orencia and RoActemra in some circumstances

25 August 2010

Bristol-Myers Squibb’s Orencia gets expanded indication in Europe and Reyataz cleared for pediatric use

8 July 2010

UK’s NICE unable to recommend GlaxoSmithKline’s leukemia drug Arzerra, but backs Lilly’s Alimta for lung cancer; reverses decision on B-MS’ Orencia

25 June 2010

Europe’s CHMP adopts opinions on Allergan’s Ozurdex and generic leflunomide and use extensions; proposes Zeffix restriction; backs rotavirus vaccine use

24 May 2010

Bristol-Myers Squibb’ post-Plavix 2013 EPS forecast to drop to $1.95, but still exceeds expectations; promising R&D pipeline

5 March 2010

Patient groups take issue with the UK NICE’s reassessment of switching on RA drugs and decision on leukemia therapy azacitidine

4 March 2010

Bristol-Myers Squibb forecasts large jump in 2010 profit to range of $1.94 to $2.04 per share

29 January 2010

European Commission approves Bristol-Myers Squibb’s Orencia for combination use in pJIA

26 January 2010

Insight on how rheumatologists are utilizing biologics in RA treatment

16 December 2009

Judgement in favor of UK NICE on judicial review of B-MS Orencia for rheumatoid arthritis guidance

9 November 2009

Bristol-Myers sees 64% leap in 3rd quarter 2009 ongoing earnings

23 October 2009

India's rheumatoid arthritis drug market will more than double by 2013

14 October 2009

B-MS' 1st qtr hit by tax and legal costs

29 April 2009

B-MS to use XDx tests to develop Orencia

19 January 2009

B-MS' Orencia almost doubles RA remission

3 November 2008

Bristol-Myers Squibb's 3rd-qtr 2008 profit triples due to big gain from $4.1B sales of ConvaTec

3 November 2008

B-MS presents JIA drug QOL data at ACR

3 November 2008

B-MS' profit accelerates on good exchange rate

4 August 2008

NICE rejects second-line use of TNF-alpha drugs

28 July 2008

Orencia inhibits joint damage through three years

23 June 2008

New data presented at EULAR questions value of repeat TNF blockers for RA

23 June 2008

Roche's Actemra inhibits RA joint damage to boost QoL, according to Ph III LITHE data

19 May 2008

"Condemned to a life of misery" by UK's NICE

5 May 2008

FDA approves B-MS' Orencia for JIA

14 April 2008

Combining medications often best strategy to battle rheumatoid arthritis; study

3 December 2007

Strong long-term efficacy and safety data for Orencia

19 November 2007

Continued rebound of Plavix lifts Bristol-Myers Squibb's third quarter

5 November 2007

US FDA accepts sBLA for B-MS' Orencia

13 August 2007

EC clears B-MS' Orencia for RA

4 June 2007

B-MS' Orencia gets stronger US labeling

7 May 2007

Bristol-Myers Squibb's 1st-qtr sales and profits down, as takeover talk continues

7 May 2007

B-MS completes land purchase for new production site

26 February 2007

RA biological competitors spent $195M on promotion

8 January 2007

B-MS reports two-year Orencia data in RA

20 November 2006

Bristol-Myers Squibb's 3rd-qtr income down 65% to $388M, as sales fall 12.5%

6 November 2006

Bristol-Myers Squibb's 2nd-qtr EPS plunges on flat sales and tax increase

7 August 2006

B-MS discusses two-year Orencia trial data

3 July 2006

2006 EULAR congress sees wealth of new drugs for the autoimmune disease market

3 July 2006

B-MS's Orencia performs well in trials

15 May 2006

FDA approves B-MS sBLA for Orencia for third-party production

15 May 2006

Early development of six pharma agents urged in Japan

8 May 2006

B-MS to invest $200M in Puerto Rico plant expansion

3 April 2006

Avidex sees positive data from RhuDex trials

20 March 2006

B-MS to build new $660M US biologics plant

13 March 2006

4th-qtr 2005 sales drop 1% for B-MS, as patents lost

30 January 2006

Repligen claims patent suit on B-MS' Orencia

16 January 2006

B-MS completes Orencia sBLA

9 January 2006

B-MS's arthritis drug Orencia gets FDA go ahead

9 January 2006

B-MS announces cost-cutting plans

19 December 2005

US FDA advisers urge appro of B-MS' Orencia

12 September 2005

Celltrion to make biologicals for B-MS

27 June 2005

B-MS' Abatacept inhibits RA damage

20 June 2005

UPDATE: B-MS submits muraglitazar in the USA

10 January 2005

B-MS submits muraglitazar in the USA

10 January 2005

B-MS' abatacept shows promise for rheumatoid arthritis in Phase III trials

25 October 2004

B-MS reacts to WSJ

12 July 2004

Showing 1-68 of 68 articles

Go to beginningPrevious
  • 1
NextGo to end